Auxilium Pharmaceuticals, Inc.

auxilium.com

Auxilium Pharmaceuticals, Inc. is a fully integrated specialty biopharmaceutical company with a focus on developing and commercializing innovative products for specialist audiences. At Auxilium, everything we do is inspired by a commitment to our mission, vision and values.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Pharma Tech

N-LOREM FOUNDATION PARTNERS WITH ALNYLAM TO EXPAND TECHNOLOGY ACCESS TO RNAI THERAPEUTICS FOR PATIENTS WITH NANO-RARE DISEASES

n-Lorem a nonprofit Foundation | January 20, 2022

news image

n-Lorem, a nonprofit Foundation, discovering and providing experimental antisense oligonucleotide medicines to nano-rare disease patients for free, for life, today announced a new partnership with Alnylam Pharmaceuticals Inc. “Discovering, developing and providing individualized medicines for nano-rare patients is a monumental task. At n-Lorem, using ASO technology, we take advantage of three decades of experience, unparalleled quality control and integrated safety databases...

Read More

Business Insights

THERAPEUTICSMD AND EW HEALTHCARE PARTNERS ANNOUNCE DEFINITIVE AGREEMENT FOR EW HEALTHCARE PARTNERS TO ACQUIRE THERAPEUTICSMD

TherapeuticsMD, Inc | June 01, 2022

news image

TherapeuticsMD, Inc. an innovative, leading women’s healthcare company, announced that it has entered into a definitive merger agreement to be acquired by an affiliate of EW Healthcare Partners, a private equity firm dedicated to making investments in rapidly growing healthcare companies. Under the terms of the transaction, which has been unanimously approved by TXMD’s board of directors, EW Healthcare Partners will commence a tender offer to acquire all outstanding sh...

Read More

Business Insights, PHARMA TECH

SIMULATIONS PLUS RECEIVES U.S. FDA RENEWAL FOR DILISYM SOFTWARE LICENSES

businesswire | April 19, 2023

news image

Simulations Plus, Inc. a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, announced that the U.S. FDA has renewed its licenses to the DILIsym® software platform, the flagship quantitative systems toxicology (QST) software for predicting and investigating drug-induced liver injury (DILI). The one-year renewal provides continued access to DILIsym software for authorized FDA employees across all FDA divisions. Dr. Paul B....

Read More

Pharma Tech

INNATE PHARMA TO PRESENT LACUTAMAB PTCL PHASE 1B DESIGN AND ANKET™ PLATFORM AT ESMO 2022

Innate Pharma | September 06, 2022

news image

Innate Pharma SA announced that the following presentations will be presented at the ESMO Annual Meeting 2022 taking place from 9 to 13 September 2022, in Paris, France. About Lacutamab Lacutamab is a first-in-class anti-KIR3DL2 humanized cytotoxicity-inducing antibody that is currently in clinical trials for treatment of cutaneous T-cell lymphoma an orphan disease, and peripheral T cell lymphoma. Rare cutaneous lymphomas of T lymphocytes has a poor prognos...

Read More
news image

Pharma Tech

N-LOREM FOUNDATION PARTNERS WITH ALNYLAM TO EXPAND TECHNOLOGY ACCESS TO RNAI THERAPEUTICS FOR PATIENTS WITH NANO-RARE DISEASES

n-Lorem a nonprofit Foundation | January 20, 2022

n-Lorem, a nonprofit Foundation, discovering and providing experimental antisense oligonucleotide medicines to nano-rare disease patients for free, for life, today announced a new partnership with Alnylam Pharmaceuticals Inc. “Discovering, developing and providing individualized medicines for nano-rare patients is a monumental task. At n-Lorem, using ASO technology, we take advantage of three decades of experience, unparalleled quality control and integrated safety databases...

Read More
news image

Business Insights

THERAPEUTICSMD AND EW HEALTHCARE PARTNERS ANNOUNCE DEFINITIVE AGREEMENT FOR EW HEALTHCARE PARTNERS TO ACQUIRE THERAPEUTICSMD

TherapeuticsMD, Inc | June 01, 2022

TherapeuticsMD, Inc. an innovative, leading women’s healthcare company, announced that it has entered into a definitive merger agreement to be acquired by an affiliate of EW Healthcare Partners, a private equity firm dedicated to making investments in rapidly growing healthcare companies. Under the terms of the transaction, which has been unanimously approved by TXMD’s board of directors, EW Healthcare Partners will commence a tender offer to acquire all outstanding sh...

Read More
news image

Business Insights, PHARMA TECH

SIMULATIONS PLUS RECEIVES U.S. FDA RENEWAL FOR DILISYM SOFTWARE LICENSES

businesswire | April 19, 2023

Simulations Plus, Inc. a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, announced that the U.S. FDA has renewed its licenses to the DILIsym® software platform, the flagship quantitative systems toxicology (QST) software for predicting and investigating drug-induced liver injury (DILI). The one-year renewal provides continued access to DILIsym software for authorized FDA employees across all FDA divisions. Dr. Paul B....

Read More
news image

Pharma Tech

INNATE PHARMA TO PRESENT LACUTAMAB PTCL PHASE 1B DESIGN AND ANKET™ PLATFORM AT ESMO 2022

Innate Pharma | September 06, 2022

Innate Pharma SA announced that the following presentations will be presented at the ESMO Annual Meeting 2022 taking place from 9 to 13 September 2022, in Paris, France. About Lacutamab Lacutamab is a first-in-class anti-KIR3DL2 humanized cytotoxicity-inducing antibody that is currently in clinical trials for treatment of cutaneous T-cell lymphoma an orphan disease, and peripheral T cell lymphoma. Rare cutaneous lymphomas of T lymphocytes has a poor prognos...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us